Atacicept: Phase II discontinued

Zymogenetics disclosed in an SEC filing that partner Merck Serono S.A. discontinued ongoing studies for atacicept to treat MS. Merck made the decision after an Independent DMC "determined that the risk/benefit relationship did not justify the continuation of these studies." ...